This problem is relevant for cohorts of patients with locally advanced prostate cancer (LAPC) without lymphatic dissemination (LD), and particularly for those patients with the most widely represented molecular subtype of PC associated with the expression of the fusion transcript TMPRSS2-ERG (approximately 40% of PC patients). This evidence concerns the gene TMPRSS2 and prostate cancer.